eGenesis, Inc.

We’re excited to announce our $191M Series D financing round led by Lux Capital with participation from existing investors ARCH Venture Partners, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, and Leaps by Bayer as well as new investors DaVita Kidney Care, Eisai US Innovation, NATCO Pharma and Parkwood Corporation. Proceeds will be used to advance the company’s lead product candidate, EGEN-2784, to a first-in-human study for kidney transplant. The funding will also be used to advance pipeline programs as well as scale production. Read the release: 👇👇 https://lnkd.in/dU6QT-3E #organ #transplantation #biotech #funding

Nature Lab Animal speaks with our CEO Michael Curtis and SVP, Innovation Wenning Qin for this technology feature on organ transplantation. “The field of xenotransplantation, once relegated to the fringes of medicine, has grown by leaps and bounds over the past few years. Several companies in the United States, China, New Zealand and elsewhere are racing to breed and genetically engineer pigs so that their organs are better suited for human transplantation. Their aim — to fill the desperate need for organ transplants — is especially urgent when considering that in the United States alone, 17 people die each day waiting for an organ donation.” Read the article: 👇👇 https://lnkd.in/eH8fkCK8

Thanks Wyss Institute at Harvard University for mentioning our work at eGenesis, Inc. 🧬🧬 “In 2018, eGenesis launched from the Wyss and HMS to build on this feat in genome engineering, and further develop safe and effective pig organs as transplants for human patients. In the subsequent years, doctors from MGH, scientists from eGenesis, and Church continued to collaborate on this groundbreaking research.” Sharing the article: 👇👇 https://lnkd.in/efX_G7Xn

Our CEO Michael Curtis spoke at the LSX USA Congress today on a panel about establishing outstanding biotech executive teams. 🧬🧬 Great discussion and thanks to everyone who joined us today! Hope to see you all at the next event. #LSXCongress

Our CEO Michael Curtis will be speaking at the LSX USA Congress this Thursday, Sept 12, 11:50am - 12:40pm. Cultivating Success: Establishing an Outstanding #Biotech Executive Team What do you get if you combine excellent company culture, core values and principles, and a diverse and representative executive team? Probably a biotech company on their way to do great and inspiring things. This panel will explore experience and knowledge in building exceptional leadership teams and the importance of company culture in a wider context. Expect to hear strategies, challenges and success stories that contribute to fostering success in this rapidly competing sector. Sharing more info: https://lnkd.in/ep8iauyH

eGenesis, Inc., a biotechnology company pioneering solutions for the global organ shortage, has secured $191 million in Series D financing. This funding will propel the development of EGEN-2784, a genetically engineered kidney for transplantation. Lux Capital led the financing, backed by existing and new investors. CEO Mike Curtis expressed gratitude for the continued support. Through breakthroughs in genome editing, eGenesis has created organs compatible with humans, offering a promising solution to the organ shortage crisis. The recent success of the world’s first porcine kidney transplant in a living patient represents a significant milestone in cross-species transplantation, authorized by the FDA in March 2024. With over 800,000 Americans and millions worldwide in need of kidney transplants, eGenesis's EGEN-2784 presents a potential answer to the urgent demand. These genetically modified kidneys aim to overcome rejection issues and provide a viable alternative to traditional donor organs. The innovative approach includes genetic edits to enhance compatibility and ensure successful transplantation. Learn more about eGenesis's groundbreaking work and the future of organ transplantation: https://lnkd.in/d7GtCrWX James Olesen Wes Westlin Michael Curtis #Biotechnology #OrganShortage #Innovation

Thanks Crunchbase for highlighting us as one of the top 3 largest funding rounds this week! 🚀🚀 3. eGenesis, $191M, biotech: Cambridge, Massachusetts-based eGenesis, a biotech firm developing human-compatible engineered organs, closed a $191 million Series D led by Lux Capital. In March, eGenesis announced the world’s first successful transplant of a genetically engineered pig kidney to a human. The new cash will be used to advance a pipeline of programs. Founded in 2014, the company has raised $456 million, per Crunchbase. Read the article: https://lnkd.in/gxZCVtMe

Thanks NYSE for celebrating our $191M Series D funding led by Lux Capital with a trading floor takeover! 🔥🔥🔥 We’d like to thank all our supporters, partners and our incredible team - who are focused on developing a solution for the organ transplantation shortage for making this happen! Thank you all. Read our release: 👇👇👇 https://lnkd.in/eMbWhfsN

eGenesis Raises $191 Million for Gene Edited Pig Organs “This financing demonstrates the confidence that investors have in cross-species transplantation as a potential solution to the global organ crisis and in eGenesis as the leader in this sector,” said Michael Curtis, president and CEO, eGenesis, Inc. The proceeds will go toward advancing eGenesis’s lead candidate for kidney transplant.

This edition of #FundingFriday is headlined by eGenesis, Inc.'s $191M Series D financing led by Lux Capital. #MassBioMember eGenesis, which has now raised about $450M, is the biotech behind the technology that enabled the first-ever pig-to-human kidney transplant earlier this year. More from Hannah Green in the BBJ: https://lnkd.in/d9cHXkf7. “This financing demonstrates the confidence that investors have in cross-species transplantation as a potential solution to the global organ crisis and in eGenesis as the leader in this sector,” eGenesis CEO Mike Curtis said in the announcement. “We are thrilled to work with Lux Capital and this world-class syndicate to advance our lead program to formal clinical trials. With this support, we are one step closer to bringing a solution to help patients suffering from organ failure.” All told, more than $236M in VC and other private funding was reported by A-Synaptic, CytoTronics, eGenesis, Prana Biosciences Inc., Savran Technologies Inc., Somite Therapeutics, and Superluminal Medicines Inc. over the last couple weeks.